Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Baxter
Accenture
Dow
Chubb
Queensland Health
Johnson and Johnson
Mallinckrodt
Medtronic

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: RE43390

« Back to Dashboard

Which drugs does patent RE43390 protect, and when does it expire?

Patent RE43390 protects ALTABAX and is included in one NDA.

This patent has fifty patent family members in thirty-five countries.
Summary for Patent: RE43390
Title:Pleuromutilin derivatives as antimicrobials
Abstract: The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy.
Inventor(s): Berry; Valerie Joan (Chester Springs, PA), Dabbs; Steven (Harlow, GB), Frydrych; Colin Henry (Sawbridgeworth, GB), Hunt; Eric (Great Dunmow, GB), Sanderson; Francis Dominic (Harlow, GB), Woodnutt; Gary (Chester Springs, PA)
Assignee: GlaxoSmithKline LLC (Philadelphia, PA) SmithKline Beecham Limited (Brentford, Middlesex, GB)
Application Number:13/102,156
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use; Dosage form;

Drugs Protected by US Patent RE43390

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Aqua Pharms Llc ALTABAX retapamulin OINTMENT;TOPICAL 022055-001 Apr 12, 2007 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: RE43390

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9722817Oct 29, 1997
United Kingdom9813689Jun 25, 1998
PCT Information
PCT FiledOctober 27, 1998PCT Application Number:PCT/GB98/03211
PCT Publication Date:May 06, 1999PCT Publication Number: WO99/21855

Non-Orange Book US Patents Family Members for Patent RE43390

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,281,226 Pleuromutilin derivatives as antimicrobials ➤ Sign Up
RE39128 Pleuromutilin derivatives as antimicrobials ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
QuintilesIMS
Dow
Chinese Patent Office
Baxter
Chubb
Argus Health
Queensland Health
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.